MEDIA
Official press releases and media coverage

Our work is regularly covered by the leading media organisations around the world. This section serves as a repository of all official press releases issued by our Corporate Communications and Investor Relations teams. You can also browse through the selection of media articles on Laurus Labs and relevant reportage.

25 Jan 2024
Press Release - JV Agreement with KRKA


24 Jan 2024
Press Release - Laurus Labs Financial Results Q3 FY 2024


20 Oct 2023
Press Release - Financial Results Q2 FY 2024


27 Jul 2023
Press Release - Financial Results Q1 FY 2024


22 Jun 2023
Press Release - Newspaper Advertisement


19 Jun 2023
Press Release - Laurus Labs signs Memorandum of Agreement (MOA) with IIT Kanpur for novel gene therapy assets


31 May 2023
Press Release - Laurus Labs further invests in Cell and Gene therapy company ImmunoACT; to hold 33.86% stake post- completion of the transaction


02 May 2023
Press Release - Laurus Labs receives USFDA tentative approval for the World's First Paediatric ARV Oral Dispersible Film (ODF) drug, Dolutegravir 5mg and 10mg in HIV/AIDS treatment


27 Apr 2023
Laurus Labs Financial Results Q4 FY 2023 Press Release


30 Jan 2023
Laurus Labs Financial Results Q3 FY 2023 Press Release


21 Oct 2022
Laurus Labs Financial Results Q2 FY 2023 Press Release


27 Jul 2022
Laurus Labs Financial Results Q1 FY 2023 Press Release


28 Apr 2022
Press Release - Q4 Press Release FY 2022


27 Nov 2021
Press Release - Laurus Labs Financial Results Q3 FY 2022


21 Nov 2021
Press Release - Laurus Labs signs an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication


19 Nov 2021
Press Release titled - Laurus Labs acquires substantial minority stake in a CAR-T cell therapy company - ImmunoACT


28 Oct 2021
Healthy Growth momentum with 17% revenue growth for H1FY22


14 Sep 2021
Press Release - Laurus Labs, Unitaid and the Clinton Health Access Initiative, announce agreement to accelerate development of best-in-class second- and third-line HIV medication for children


29 Jul 2021
Press Release - Laurus Labs Financial Results Q1 FY 2022


02 Jul 2021
Press Release- Laurus Labs receives the License to manufacture and market 2-Deoxy-D-Glucose (2DG) in India, from DRDO


29 Apr 2021
Laurus Labs Financial Results Q4 FY 2021 Press Release


04 Mar 2021
Laurus labs promoters, Dr.Satyanarayana chava, founder and ceo & Mrs. Nagarani chava, promoter, are set to release the pledge of shares of the company


10 Feb 2021
Laurus Labs wins coveted Golden Peacock Award for Excellence in Corporate Governance


28 Jan 2021
Revenue growth of 76% and PAT growth of 274% in Q3 FY21


25 Nov 2020
Laurus Labs enters the rapidly growing biotechnology segment by acquiring a majority stake in Richcore Lifesciences


29 Oct 2020
Laurus Labs Press Release Board Meeting Oct 29 2020


29 Oct 2020
Q2 H1 FY21 Press Release Oct 29 2020


30 Jul 2020
Press Release - Strong Revenue growth of 77% and PAT growth of 1047%


19 May 2020
Press Release - Laurus Labs receives USFDA approvals for ANDAs TLE 400 and TLE 600 tablets.


30 Apr 2020
Press Release - Highest Ever Profit after Tax at INR 2,553 mn in FY20, growth of 172%


27 Mar 2020
Rising Pharmaceuticals and Laurus Labs Partner to Support the University of Minnesota to Explore the Prophylaxis Effect of Hydroxychloroquine in Essential Health Care Workers


26 Mar 2020
Laurus Labs donates Hydroxychloroquine (HCQ) IP 200mg tablets & INR 50 lakhs fund to fight the COVID-19 pandemic in Telangana and Andhra Pradesh States


30 Jan 2020
Press Release - PROFIT AFTER TAX AT INR 73.5 crs in Q3 FY20 with a growth of 313 %


21 Nov 2019
Laurus Labs completes US FDA, pre-approval inspection (P AI), for an API manufactured at its units 1&3, Visakhapatnam


08 Nov 2019
Laurus Labs completed the USFDA Inspection of its FDF & API Integrated Facility, Unit 2, at Visakhapatnam


30 Oct 2019
Laurus Labs Financial Results Q2 FY 2020 Press Release


18 Sep 2019
Laurus Labs to acquire the Subsidiary Company of Aspen Pharmacare, South Africa


05 Sep 2019
Laurus Labs receives an EIR from USFDA for its API Units 1 & 3 and also received an ERP approval for fixed dose combination TLE400 from Global Fund


02 Aug 2019
Q1 FY20 Results: Revenues up by 2 percent


22 July 2019
Laurus Labs' exclusive distribution partner Rising Pharmaceuticals, launches Pregabalin Capsules in US market


12 July 2019
Laurus Labs completed the US FDA inspection of Unit 4 at Visakhapatnam


14 June 2019
USFDA inspection of API facilites Unit 1 & 3 at Visakhapatnam


02 May 2019
FY 19 : Laurus Labs revenues up by 11.5 percent in Q4


26 Mar 2019
FY 19 : Laurus Labs enters into strategic partnership agreement with the Global Fund


11 Mar 2019
FY 19 : Laurus Labs receives two approvals from USFDA


3 Feb 2019
FY 19 : Laurus Labs received tentative approval from USFDA under PEPFAR for TLD FDC


3 Feb 2019
FY 19 : USFDA Approval for TLD Tablets and EIR from USFDA


31 Jan 2019
FY 19 : Laurus Labs Revenue Grew 11% in Q3 FY19


1 Dec 2018
FY 18 : Laurus Labs and Aspen Pharmacare launch an improved triple combination HIV drug in South Africa


1 Nov 2018
FY 18 : Laurus Labs Financial Results Q2 FY2019 Press Release


23 Oct 2018
FY 18 : Press Release Laurus Labs Oct 23 2018


29 Aug 2018
FY 18 : Press Release 29 Aug 2018 - Metformin USFDA Approval


3 Aug 2018
FY 18 : Press Release of Q1 Results 2018-19


10 May 2018
FY 17 : Press Release of Q4 Results 2017-18


1 March 2018
FY 17 : Intimation of completion of USFDA inspection of unit2 with no observations


29 January 2018
FY 17 : Press Release of Q3 9M Results 2017-18


17 January 2018
FY 17 : LAURUS LABS CERTIFIED AS THE “GREAT PLACE TO WORK” IN THE LARGE SIZED ORGANISATIONCATEGORY IN INDIA


9 November 2017
FY 17 : Q2 H1 Results 2017-18 Press Release


10 November 2017
FY 17 : Analyst and Investor Meet Intimation 10-11-2017


15 September 2017
FY 17 : Unit 2 receives EIR from USFDA and completes German Regulatory Authority inspection;


18 August 2017
FY 17 : Laurus Labs completed the USFDA inspection of its API facilities Unit 1 & 3 at Visakhapatnam


10 August 2017
FY 17 : Press Release of Q1 Results 2017-18


5 July 2017
FY 17 : Laurus Labs Credit Rating Improved


18 May 2017
FY 17 : Laurus Labs PAT grows by 40%


9 February 2017
FY 17 : Laurus Labs demonstrates strong Q3 growth In the first quarterly results after successful IPO


23 Jun 2021
Dr. Satyanarayana Chava's interview on Bloomberg Asia


29 Jan 2021
ET Now News


03 Aug 2020
Laurus Labs in focus, zooms over 15%; stock hits all-time high


03 Aug 2020
Story on Laurus Labs in Financial Express.


03 Aug 2020
Q1 net more than annual profit! This API maker is creating a splash on Dalal Street


31 Jul 2020
Blockbuster Q1 For Laurus Labs | Satyanarayana Chava of Laurus Labs To ET NOW


31 Jul 2020
What led to a blockbuster quarter for Laurus Labs


31 Jul 2020
Trending stocks: Laurus Labs shares surge over 15%


31 Jul 2020
అత్యంత ఆకర్షణీయంగా లారస్ ల్యాబ్స్ ఫలితాలు


30 Jul 2020
Laurus Labs net up 11 times to Rs 172 Cr in Q1


30 Jul 2020
Laurus Labs standalone net profit rises 832.35% in the June 2020 quarter


30 Jul 2020
Laurus Labs Q1 profit at Rs 172 crore


30 Jul 2020
Gainers & Losers: 10 stocks that moved the most on July 30


30 Jul 2020
Laurus Labs' net up 11 times to Rs 172 crore in Q1


30 Jul 2020
Laurus Labs consolidated net profit rises 1037.62% in the June 2020 quarter


26 Feb 2020
Laurus Labs banking on vertical integration to crack anti-HIV tenders and US formulations mkts


31 Jan 2020
Laurus Labs Standalone December 2019 Net Sales at Rs 720.99 crore, up 40.61% Y-o-Y


30 Jan 2020
Laurus Labs Q3 net profit rises 4-fold at Rs 73 crore


30 Jan 2020
Laurus Labs net trebles at Rs. 73.5 crore


28 Dec 2019
Laurus Labs eyes bigger play in generic formulations segment


11 Nov 2019
Laurus Labs shares up on USFDA observations on Visakhapatnam unit


01 Nov 2019
Laurus Labs consolidated net profit rises 248.86% in the September 2019 quarter


01 Nov 2019
Laurus Labs Standalone September 2019 Net Sales at Rs 705.86 crore, up 22.84% Y-o-Y


31 Oct 2019
Laurus Labs Ltd crosses revenue of Rs. 700 crores in Q2 FY20


23 Oct 2019
CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited


18 Sep 2019
Laurus Labs to acquire South Africa's Aspen Pharmacare subsidiary


18 Sep 2019
Warburg Pincus-backed Laurus Labs buys South African firm


05 Sep 2019
Laurus Labs gets approval from the FDA


29 Aug 2019
Laurus Labs gets USFDA approval for Metformin tablets


05 Aug 2019
Laurus Labs Ltd CEO Satyanarayana Chava speaks on Q1 results


22 Jul 2019
Laurus Labs partner Rising Pharma launches neuropathic pain capsules in US


12 Jul 2019
Laurus Labs gets USFDA nod for Unit-4


12 Jul 2019
Laurus Labs Vizag unit completes USFDA inspection


15 Jun 2019
Laurus Labs gets 2 USFDA observations for its API facilities in Visakhapatnam


27 March 2019
Laurus Labs joins hand with Global Fund to supply drugs


26 March 2019
Laurus Labs seals deal with Global Fund to supply ARV combination medicine


26 March 2019
Laurus Labs jumps 4% on strategic partnership with Global Fund


26 March 2019
Larus Labs enters agreement with Global Fund for supply of AIDS drugs


26 March 2019
Laurus Labs firms up after partnership with Global Fund


26 March 2019
Laurus Labs in pact with The Global Fund


26 March 2019
Laurus Labs enters into strategic partnership agreement with Global Fund


14 February 2019
Laurus Labs invests over $100 million on formulation biz


3 February 2019
Laurus Labs gets USFDA approval for HIV drug


3 February 2019
Laurus Labs gets USFDA nod for HIV drug


2 December 2018
Laurus Labs-Aspen Pharmacare launch HIV drug in South Africa


3 November 2018
Laurus Labs Vizag API unit gets 1 USFDA observation


2 November 2018
Laurus Labs Vizag API unit gets 1 USFDA observation


23 October 2018
Laurus Labs to expand its footprint in US, China


30 August 2018
Laurus Labs gets USFDA nod for diabetes drug


30 August 2018
Laurus Labs rises nearly 6% post USFDA approval for diabetes drug


29 August 2018
Laurus Labs gets USFDA nod for diabetes drug


29 August 2018
Laurus Labs gets USFDA nod for diabetes drug


11 August 2017
Expect to get 2 ANDA approvals in FY18: Laurus Labs


11 August 2017
LAURAS LABS Q1: PROFIT JUMPS 51%


22 May 2017
Laurus Labs Q4 net rises 39%


19 May 2017
Laurus Labs says API facility of Unit 2 completed successful USFDA inspection


19 May 2017
Laurus Labs Vizag unit clears USFDA inspection ahead of debut in US generics market


Laurus Labs standalone net profit rises 39.11% in the March 2017 quarter


31 March 2017
Laurus Labs' PAT increases by 39% to Rs 74.3-cr.


18 May 2017
Laurus Labs posts Rs 74 crore net profit in Q4


27 March 2017
Citi bullish on Laurus; return ratios will improve post formulations: Satyanarayana Chava, Founder & CEO


Laurus Labs December quarter net up 17.5% to Rs 47 crore


10 February 2017
Laurus Labs hopes better profits in Q4 with lower interest outgo after debt retirement


10 February 2017
Laurus Labs December quarter net up 17.5% to Rs 47 crore


10 February 2017
Laurus Labs Q3 net up 18%


Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO


9 February 2017
Laurus Labs net profit up 17.5% to Rs 47.2 crore in Q3


9 February 2017
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO


10 February 2017
Laurus Labs December quarter net up 17.5% to Rs 47 crore


Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO


11 February 2017
Laurus Labs December quarter net up 17.5% to Rs 47 crore


13 February 2017
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO


9 February 2017
Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO


Laurus Labs Demonstrates Strong Q3 Growth In The First Quarterly Results After Successful IPO

Videos:

Latest Tweets